IPH 2101

Generic Name
IPH 2101
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1000676-42-5
Unique Ingredient Identifier
5Q686XLG8L
Background

IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

Indication

Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.

Associated Conditions
-
Associated Therapies
-

A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-12-08
Last Posted Date
2014-02-28
Lead Sponsor
Innate Pharma
Target Recruit Count
21
Registration Number
NCT01256073
Locations
πŸ‡«πŸ‡·

Hopital Dupuytren, LIMOGES Cedex, France

πŸ‡«πŸ‡·

Institut Paoli-Calmettes, Marseille, Marseille Cedex 09, France

πŸ‡«πŸ‡·

C.H.R.U. de Nantes - Hotel Dieu, NANTES Cedex 1, France

and more 3 locations

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-10-18
Last Posted Date
2014-05-09
Lead Sponsor
Innate Pharma
Target Recruit Count
30
Registration Number
NCT01222286
Locations
πŸ‡ΊπŸ‡Έ

Sarah Cannon Research Institute, Nashville, Tennessee, United States

πŸ‡ΊπŸ‡Έ

Ohio State University, Columbus, Ohio, United States

πŸ‡ΊπŸ‡Έ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-10-22
Last Posted Date
2016-03-24
Lead Sponsor
Innate Pharma
Target Recruit Count
27
Registration Number
NCT00999830
Locations
πŸ‡«πŸ‡·

CHU Nancy, Nancy, France

πŸ‡«πŸ‡·

Hopital Saint Louis, Paris, France

πŸ‡«πŸ‡·

Institut Paoli Calmettes, Marseille, France

and more 6 locations
Β© Copyright 2024. All Rights Reserved by MedPath